Roche's Avastin prolongs colorectal cancer patients' survival ZURICH (Reuters) - A new study of Roche Holding AG's cancer drug Avastin showed significantly improved survival in patients with metastatic colorectal cancer irrespective of K-Ras gene mutations, the Basel-based drug maker said on Monday.
TopAbstracts in Glaucoma 06/30/2008 TopAbstracts in Glaucoma are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 28 days.Over 2000 peer-reviewed...
Evaluation of the embryotoxic potency of compounds in a newly revised high throughput embryonic stem cell test Address: Johnson & Johnson Pharmaceutical Research & Development (J&J-PRD), Department of Mechanistic Toxicology, Turnhoutseweg 30, Beerse, B-2340, Belgium, Telephone 0032-14608329, Fax 0032-14605150 * Corresponding author; e...
Breast Cancer - Research from M. Campone and co-researchers provides new data on breast cancer Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00.
Breast Cancer Research from M.
Campone and co...
Gastric Cancer: Oral Fluoropyrimidine S-1, Good Standard Therapy in Japan, But Not At Least As Yet in US NEW YORK CITY-Oral fluoropyrimidine S-1, most widely used against advanced gastric cancer in Japan, is effective as a new standard therapy for patients with advanced and postoperative gastric cancer, according to research discussed here at...
Adding Taxane to Anthracycline-Based Therapy Does Not Improve Outcomes SAN ANTONIO-Giving a taxane following standard anthracycline-based chemotherapy for early breast cancer will not improve outcomes, suggest results of a 104-center, British study presented at the San Antonio Breast Cancer Symposium.There...
New ASCO President Richard L. Schilsky on His Vision for ASCO, Strategic Planning, Setting Priorities, & the P [THE ONCOLOGY TIMES INTERVIEW] Rosenthal, Eric T.Special Correspondent Throughout his career in academic medicine-since starting medical school at the University of Chicago where he has been a long-time faculty member and held leadership...
Adventrx Pharma Reveals Data From Discontinued Clinical TrialFor Colorectal Cancer (RTTNews) - Adventrx Pharmaceuticals, Inc.(ANX: News, Chart, Quote ) Tuesday released preliminary response rate data from the discontinued phase 3 clinical trial of ANX-510 or CoFactor as a first line treatment of colorectal cancer.
Novel Assay Allows Individualized Chemotherapy Management Monitoring The 5-FU Personalized Chemotherapy Management (PCM) assay, intended for use on the Olympus AU400 clinical chemistry analyzer, allows oncologists who prescribe 5-fluorouracil (5-FU) continuous infusion regimens (alone or in combination...
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer PITTSBURGH, July 1 /PRNewswire/ -- Precision Therapeutics Inc.announced today that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with...
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 ...
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer PITTSBURGH, July 1 /PRNewswire/ -- Precision Therapeutics Inc.announced today that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with...
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5...
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.(Amex: ANX - News) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate...
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5...
Roche's Avastin prolongs colorectal cancer patients survival ZURICH, June 30 (Reuters) - A new Phase III study of Roche Holding AG's (ROG.VX: Quote, Profile, Research, Stock Buzz) cancer drug Avastin showed significantly improved survival in patients with metastatic colorectal cancer irrespective of K...
TopAbstracts in Liver Cancer 06/26/2008 TopAbstracts in Liver Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed...
Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene MutationX/fo Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation BASEL, June 26/ PRNewswire-AsiaNet/ -- - For Non-US Media Only - Avastin is the Only Biologic Proven to Extend Life in Patients With...
Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients Irrespective of K-Ras Gene Mutation Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation BASEL, June 26/ PRNewswire-AsiaNet/ -- - For Non-US Media Only - Avastin is the Only Biologic Proven to Extend Life in Patients With...
Studies from Seoul National University yield new data on gastric cancer - (NewsRx.com) -- ADVENTRX Pharmaceuticals, Inc.(AMEX:ANX) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic colorectal cancer.
Overall...
COMMUNIQUE: PR Newswire: Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective o - Avastin is the Only Biologic Proven to Extend Life in Patients With Normal K-Ras Gene Data presented today at the 10th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona confirm that Avastin (bevacizumab) significantly improves...
COMMUNIQUE: PR Newswire: Bowel Cancer Patients Live Longer Taking Xeloda - Analysis Confirms That Oral Xeloda is Superior to IV 5-FU - Not for US Media A pre-planned multivariate analysis of the five-year follow-up data shows that patients receiving chemotherapy after-surgery to treat colon cancer, are more...
Colon Cancer - Findings from University of Pisa in colon cancer reported In this recent report, researchers in Pisa, Italy conducted a study 'To evaluate 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) pharmacolkinetics and (DFS) in patients given -based within a nonrandomized, retrospective,...
Bisphosphonates' Growing Role in Breast Cancer Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patientspharmacists need to recommend appropriate screening and treatment.
[Articles] Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemor Jaffer A.Ajani,* Kathryn Winter, Ritsuko Komaki, David P.
Kelsen, Bruce D.
Minsky, Zhongxing Liao, Jeffrey Bradley, Mitchel Fromm, David Hornback, and Christopher G.
Willett From The University of Texas M.D.
Anderson Cancer Center...
